CA2220339A1 - Toxin conjugates having a spacer comprising polyalkylene glycol and peptide - Google Patents
Toxin conjugates having a spacer comprising polyalkylene glycol and peptideInfo
- Publication number
- CA2220339A1 CA2220339A1 CA002220339A CA2220339A CA2220339A1 CA 2220339 A1 CA2220339 A1 CA 2220339A1 CA 002220339 A CA002220339 A CA 002220339A CA 2220339 A CA2220339 A CA 2220339A CA 2220339 A1 CA2220339 A1 CA 2220339A1
- Authority
- CA
- Canada
- Prior art keywords
- spacer
- polyalkylene glycol
- peptide
- toxin conjugates
- toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
Abstract
The present invention relates to a toxin conjugate in which a residue derived from a compound having an affinity for a target cell is bound to a toxin through a spacer comprising polyalkylene glycol and dipeptide.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP111933/95 | 1995-05-10 | ||
JP11193395 | 1995-05-10 | ||
PCT/JP1996/001241 WO1996035451A1 (en) | 1995-05-10 | 1996-05-10 | Novel toxin complex |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2220339A1 true CA2220339A1 (en) | 1996-11-14 |
CA2220339C CA2220339C (en) | 2009-10-13 |
Family
ID=14573780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002220339A Expired - Fee Related CA2220339C (en) | 1995-05-10 | 1996-05-10 | Toxin conjugates having a spacer comprising polyalkylene glycol and peptide |
Country Status (8)
Country | Link |
---|---|
US (2) | US6103236A (en) |
EP (1) | EP0867190B1 (en) |
JP (1) | JP3871713B2 (en) |
AT (1) | ATE381948T1 (en) |
CA (1) | CA2220339C (en) |
DE (1) | DE69637383T2 (en) |
ES (1) | ES2299177T3 (en) |
WO (1) | WO1996035451A1 (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7642323B2 (en) | 1997-11-06 | 2010-01-05 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
ATE411049T1 (en) * | 1998-05-20 | 2008-10-15 | Expression Genetics Inc | LACTOSE OR GALACTOSE-POLYETHYLENE GLYCOL-GRABTED POLY-L-LYSINE AS A GENE CARRIER |
DE60043021D1 (en) | 1999-05-17 | 2009-11-05 | Conjuchem Biotechnologies Inc | Long-acting peptide inhibitors of viral fusion with body cells in viral infections |
US6258133B1 (en) * | 1999-06-02 | 2001-07-10 | Chevron Chemical Company Llc | Poly (oxyalkylene) pyridyl and piperidyl ethers and fuel compositions containing the same |
US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
US7090851B1 (en) | 1999-09-10 | 2006-08-15 | Conjuchem Inc. | Long lasting fusion peptide inhibitors of viral infection |
AU784187B2 (en) | 1999-09-30 | 2006-02-16 | Kyowa Hakko Kogyo Co. Ltd. | Human type complementarity determining region transplantation antibody against ganglioside GD3 and derivatives of antibody against ganglioside GD3 |
CN1284603C (en) * | 1999-10-08 | 2006-11-15 | 内科塔治疗亚拉巴马公司 | Heterobifunctional poly(ethylene Glycol) derivatives and methods for their preparation |
CN1430603A (en) * | 2000-04-28 | 2003-07-16 | 旭化成株式会社 | Novel bicyclic compounds |
CA2443694A1 (en) * | 2001-04-09 | 2002-10-17 | Progenics Pharmaceuticals, Inc. | Anti-cd19 immunotoxins |
ATE295370T1 (en) * | 2001-05-31 | 2005-05-15 | Conjuchem Inc | LONG-ACTING FUSION PEPTIDE INHIBITORS FOR HIV INFECTION |
US6989452B2 (en) | 2001-05-31 | 2006-01-24 | Medarex, Inc. | Disulfide prodrugs and linkers and stabilizers useful therefor |
AU2005240680A1 (en) * | 2004-05-06 | 2005-11-17 | Conjuchem Biotechnologies Inc. | Compounds for specific viral target |
CN1997402B (en) * | 2004-05-19 | 2014-04-02 | 梅达雷克斯有限责任公司 | Cytotoxic compounds and conjugates |
AU2005244980B2 (en) * | 2004-05-19 | 2011-09-15 | E. R. Squibb & Sons, L.L.C. | Chemical linkers and conjugates thereof |
RU2402548C2 (en) * | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Chemical linkers and conjugates thereof |
EP1988167B1 (en) * | 2005-02-17 | 2020-04-01 | Sorbonne Universite | Intracellular inhibiting peptides |
US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
CA2623652C (en) * | 2005-09-26 | 2013-11-26 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
DK1940789T3 (en) | 2005-10-26 | 2012-03-19 | Medarex Inc | Methods and Compounds for the Preparation of CC-1065 Analogs |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
JP5312050B2 (en) | 2006-02-21 | 2013-10-09 | ネクター セラピューティクス | Split-type degradable polymers and composites produced therefrom |
MX2009002418A (en) | 2006-09-05 | 2009-04-23 | Medarex Inc | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use. |
TWI412367B (en) | 2006-12-28 | 2013-10-21 | Medarex Llc | Chemical linkers and cleavable substrates and conjugates thereof |
US20090088378A1 (en) * | 2007-01-12 | 2009-04-02 | Omar Quraishi | Long lasting inhibitors of viral infection |
KR20090122439A (en) | 2007-02-21 | 2009-11-30 | 메다렉스, 인코포레이티드 | Chemical linkers with single amino acids and conjugates thereof |
JP2010527376A (en) * | 2007-05-16 | 2010-08-12 | コンジュケム バイオテクノロジーズ インコーポレイテッド | Cysteinic acid derivatives of antiviral peptides |
CN101835496B (en) | 2007-10-23 | 2015-11-25 | 尼克塔治疗公司 | The multiarm polymers of hydroxyapatite-targeting and the conjugate by its manufacture |
WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
EP2554669B1 (en) | 2010-03-26 | 2018-09-19 | Kyowa Hakko Kirin Co., Ltd. | Novel antibody having modification site introduced therein, and antibody fragment |
CA2824143C (en) | 2011-01-14 | 2018-12-18 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
CA2891280C (en) | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
SG11201507619PA (en) | 2013-03-15 | 2015-10-29 | Ct For Drug Res And Dev | Cytotoxic and anti-mitotic compounds, and methods of using the same |
AU2014373574B2 (en) | 2013-12-27 | 2020-07-16 | Zymeworks Bc Inc. | Sulfonamide-containing linkage systems for drug conjugates |
CA2938919C (en) | 2014-02-28 | 2020-12-29 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
KR102494557B1 (en) | 2014-09-17 | 2023-02-02 | 자임워크스 비씨 인코포레이티드 | Cytotoxic and anti-mitotic compounds, and methods of using the same |
EP3319936A4 (en) | 2015-07-12 | 2019-02-06 | Suzhou M-conj Biotech Co., Ltd. | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
JP2019515677A (en) | 2016-04-26 | 2019-06-13 | アール.ピー.シェーラー テクノロジーズ エルエルシー | Antibody conjugates and methods of making and using the same |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
EP3888691A1 (en) | 2016-11-14 | 2021-10-06 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
US20230149558A1 (en) | 2020-04-24 | 2023-05-18 | The University Of Tokyo | Duocarmycin derivative and use thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU33730B (en) * | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
CA1203164A (en) * | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Antibody conjugates |
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
JPS6067433A (en) | 1983-09-24 | 1985-04-17 | Kyowa Hakko Kogyo Co Ltd | Complex of mitomycin, polysaccharide and antibody |
US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
JPS6335575A (en) | 1986-07-31 | 1988-02-16 | Kyowa Hakko Kogyo Co Ltd | Mitomycin derivative |
JPS63246336A (en) | 1986-11-10 | 1988-10-13 | Kyowa Hakko Kogyo Co Ltd | Composition containing mitomycin-antibody complex |
JPS63150282A (en) * | 1986-12-13 | 1988-06-22 | Kyowa Hakko Kogyo Co Ltd | Mitomycin derivative |
JPS63256336A (en) * | 1987-04-13 | 1988-10-24 | Yoshiaki Kakino | Method for correcting thermal displacement of ball screw in nc machine |
US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
US5169934A (en) * | 1990-05-14 | 1992-12-08 | Anergen, Inc. | Intracellularly cleavable compounds |
DE69122777T2 (en) * | 1990-07-20 | 1997-04-10 | Pharmacia & Upjohn Ab | TARGETED SPECIFIC ANTIBODY SUPERANTIGOUS CONJUGATES AND THEIR PREPARATION |
SG47099A1 (en) * | 1991-03-15 | 1998-03-20 | Amgen Boulder Inc | Pegylation of polypeptides |
CA2102808A1 (en) * | 1991-05-10 | 1992-11-11 | Hanne Bentz | Targeted delivery of bone growth factors |
US5169627A (en) * | 1991-10-28 | 1992-12-08 | Mount Sinai School Of Medicine Of The City University Of New York | Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity |
EP0571330B1 (en) * | 1992-05-22 | 1999-04-07 | Ciba SC Holding AG | High-resolution photoresist with enhanced sensitivity for I-line exposure |
JPH06335575A (en) * | 1993-05-28 | 1994-12-06 | Tokyo Electric Co Ltd | Shaver |
-
1996
- 1996-05-10 ES ES96913722T patent/ES2299177T3/en not_active Expired - Lifetime
- 1996-05-10 CA CA002220339A patent/CA2220339C/en not_active Expired - Fee Related
- 1996-05-10 JP JP53395196A patent/JP3871713B2/en not_active Expired - Fee Related
- 1996-05-10 EP EP96913722A patent/EP0867190B1/en not_active Expired - Lifetime
- 1996-05-10 AT AT96913722T patent/ATE381948T1/en not_active IP Right Cessation
- 1996-05-10 DE DE69637383T patent/DE69637383T2/en not_active Expired - Lifetime
- 1996-05-10 US US08/981,416 patent/US6103236A/en not_active Expired - Fee Related
- 1996-05-10 WO PCT/JP1996/001241 patent/WO1996035451A1/en active IP Right Grant
-
2000
- 2000-02-08 US US09/500,243 patent/US6638509B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2299177T3 (en) | 2008-05-16 |
EP0867190B1 (en) | 2007-12-26 |
CA2220339C (en) | 2009-10-13 |
ATE381948T1 (en) | 2008-01-15 |
US6103236A (en) | 2000-08-15 |
DE69637383D1 (en) | 2008-02-07 |
WO1996035451A1 (en) | 1996-11-14 |
EP0867190A1 (en) | 1998-09-30 |
EP0867190A4 (en) | 2002-01-02 |
JP3871713B2 (en) | 2007-01-24 |
US6638509B1 (en) | 2003-10-28 |
DE69637383T2 (en) | 2008-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2220339A1 (en) | Toxin conjugates having a spacer comprising polyalkylene glycol and peptide | |
ZA975533B (en) | Cyclosporin-containing pharmaceutical composition. | |
CA2279935A1 (en) | Chelating immunostimulating complexes | |
AU690148B2 (en) | Rubbery blend having low permanent compression set | |
AU7709194A (en) | Cyclosporin-containing powder composition | |
EP1188768A3 (en) | LHRH antagonist peptides | |
ZA9610070B (en) | Cyclosporin compositions. | |
AU1226297A (en) | Basic protein composition, basic peptide composition and application thereof | |
AU2466595A (en) | Hydrogen-natural gas motor fuel | |
AU5159798A (en) | Branched peptide linkers | |
AU6591694A (en) | Diesel fuel compositions | |
EP0739291A4 (en) | Engine exhaust gas deflection system | |
AU4710097A (en) | Fuel composition | |
AU1283597A (en) | Expansion chamber for two-cycle engine | |
AU4427296A (en) | Novel peptide | |
EP0921805A4 (en) | Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor | |
EP0821694A4 (en) | Conotoxin peptides | |
EP1731531A3 (en) | Multiple cytokine-antibody complexes | |
GB9508644D0 (en) | Fuel compositions | |
AU7713096A (en) | Improvements in combustion engines | |
AU6760294A (en) | Immunotherapeutic peptides derived from toxic shock syndrome toxin-1, antibodies thereto, their uses in pharmaceutical compositions and diagnosis | |
AU4285296A (en) | Bradykinin antagonist peptides containing indane-sustituted amino acids | |
EP1739090A3 (en) | Interferon-beta fusion proteins and uses | |
AU2826197A (en) | Bovine dipeptidylaminopeptidase 1 | |
CA2289460A1 (en) | Improved oil composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |